Literature DB >> 32348538

Neurodevelopmental Outcomes Following Intravitreal Bevacizumab With Laser Versus Laser Photocoagulation Alone for Retinopathy of Prematurity.

Kamran Ahmed, Anam S Ali, Neil Delwadia, Margaret A Greven.   

Abstract

BACKGROUND AND
OBJECTIVE: To assess neurodevelopmental outcomes of infants with treatment-warranted retinopathy of prematurity (TW-ROP) treated with intravitreal bevacizumab (IVB) plus diode laser photocoagulation (DLP) compared to DLP alone. PATIENTS AND METHODS: A retrospective review was performed of infants who underwent treatment for TW-ROP with IVB+DLP or DLP alone from 2010 to 2017. Baseline characteristics and coexisting medical comorbidities were recorded. The presence of neurodevelopmental delay (NDD) at 2-year follow-up and composite Bayley-III scores were recorded.
RESULTS: Sixty-six infants were included in the study; 18 received IVB+DLP, and 48 received DLP alone. Average Bayley-III scores for cognition, language, and motor, as well as rates of documental NDD, did not differ between the groups.
CONCLUSION: This study does not demonstrate an increased risk of NDD in infants with TW-ROP treated with IVB+DLP compared with DLP alone. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:220-224.]. Copyright 2020, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32348538     DOI: 10.3928/23258160-20200326-03

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging Retina        ISSN: 2325-8160            Impact factor:   1.300


  2 in total

Review 1.  Neurodevelopmental outcomes in preterm infants with retinopathy of prematurity.

Authors:  Hao Tan; Patricia Blasco; Tamorah Lewis; Susan Ostmo; Michael F Chiang; John Peter Campbell
Journal:  Surv Ophthalmol       Date:  2021-03-02       Impact factor: 6.197

2.  Postnatal Growth Trajectories and Neurodevelopmental Outcomes Following Bevacizumab Treatment for Retinopathy of Prematurity.

Authors:  David L Zhang; Hawke H Yoon; Raye-Ann O deRegnier; Jennifer Arzu; Safa Rahmani
Journal:  Clin Ophthalmol       Date:  2022-08-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.